Preserved for the Privileged: How Patent Walls Around Organ Viability Technology Are Costing Lives on the Transplant Waiting List

More than 100,000 people in the United States are currently listed for organ transplants. Each day, roughly twenty of them die waiting. The conventional explanation for this crisis centers on the chronic shortage of donated organs—a genuine and well-documented problem. Yet a secondary crisis, far less visible in public discourse, compounds the shortage: the organs that are recovered are not all treated equally. Whether a donated kidney, liver, or heart is deemed viable for transplantation depends, with increasing frequency, not solely on its biological condition but on the technological infrastructure available to the center that receives it. That infrastructure, in turn, is shaped by a patent landscape that has allowed a handful of manufacturers to exercise substantial market control over the tools that determine organ survival.

The Technology Gap in Organ Preservation

For decades, the standard approach to preserving donated organs between recovery and transplantation relied on static cold storage—a method that, while inexpensive and widely available, imposes strict time limits and is poorly suited to marginal or extended-criteria organs. The emergence of normothermic machine perfusion (NMP) and hypothermic machine perfusion (HMP) technologies has fundamentally altered what is possible. These devices maintain organs in a metabolically active or controlled-temperature state, extending viability windows, enabling real-time organ assessment, and—critically—allowing surgeons to recondition organs that would previously have been discarded.

The clinical evidence supporting these technologies is substantial. Studies published in peer-reviewed transplant medicine journals have documented meaningful reductions in delayed graft function and improved long-term outcomes for kidneys and livers preserved via machine perfusion. The technology is not experimental; it is increasingly regarded as the standard of care at well-resourced academic medical centers.

The problem is that these systems are expensive, proprietary, and controlled by a narrow group of manufacturers whose patent portfolios effectively exclude competition in key device categories. In the United States, where no federal mandate requires transplant programs to adopt or have access to specific preservation technologies, the decision to invest in machine perfusion systems is left to individual centers—decisions that are inevitably shaped by budget constraints, procurement capacity, and geographic circumstance.

A Market Structure Built on Exclusivity

The organ preservation device market in the United States exhibits characteristics that competition economists would recognize as a patent-protected oligopoly. A small number of firms hold overlapping patents on core perfusion mechanisms, proprietary perfusate formulations, and associated monitoring software. These protections, while legally standard, carry particular consequences in a medical context where there is no substitute product and where the downstream impact of access barriers is measured in patient mortality.

Smaller transplant programs—community hospitals, regional centers serving rural populations, safety-net institutions—frequently lack the capital to acquire and maintain advanced perfusion systems. Device costs can reach into the hundreds of thousands of dollars, with ongoing expenses for single-use consumables that are themselves patent-protected. For a center performing fifty transplants annually, the economics are often prohibitive. The result is a de facto two-tiered system: large academic programs with access to the full range of viability-extending technology, and smaller centers operating with tools that were considered adequate a generation ago.

This disparity has measurable consequences. Organs recovered in regions served predominantly by under-resourced centers are more likely to be assessed using static cold storage criteria alone. Marginal organs—those from older donors, donors with certain comorbidities, or those with extended warm ischemia times—are more frequently declined. Some of these organs, had they been assessed using machine perfusion, would have been deemed transplantable. The discard rate for recovered kidneys in the United States has long been a subject of concern among transplant researchers; technology access is among the underexplored structural contributors to that rate.

The European Contrast

The regulatory and procurement environment in several European countries offers a point of instructive comparison, though not a simple template for replication. In France, Spain, and the United Kingdom, national health systems or centralized procurement bodies have negotiated technology access agreements that allow broader institutional adoption of machine perfusion systems. In some cases, shared regional perfusion hubs have been established, allowing smaller centers to access advanced preservation technology without bearing the full capital cost independently.

European competition authorities have also demonstrated a greater willingness to scrutinize medical device markets for anticompetitive behavior, particularly where life-sustaining technology is involved. The European Medicines Agency and national health technology assessment bodies operate within frameworks that, while imperfect, are more structurally attentive to the intersection of intellectual property and public health outcomes than their American counterparts.

The United States has no equivalent mechanism. The Food and Drug Administration regulates device safety and efficacy but does not adjudicate market access or pricing. The federal government's role in transplant policy is largely confined to oversight of the Organ Procurement and Transplantation Network (OPTN), which sets allocation protocols but does not standardize the technological conditions under which organs are evaluated. This regulatory gap permits the current fragmentation to persist without institutional accountability.

The Human Arithmetic of Fragmentation

Aggregate transplant program data, while not always granular enough to isolate technology access as a discrete variable, nonetheless suggests patterns consistent with the disparities described above. Centers in the lowest quartile of transplant volume—which correlate imperfectly but meaningfully with resource constraints—exhibit higher organ discard rates for recovered kidneys and livers. Geographic clustering of these centers in rural states and underserved urban corridors further concentrates the burden on populations already facing elevated health risk.

For patients on the waiting list, the implications are both statistical and personal. A patient listed at a well-resourced academic center in a major metropolitan area is more likely to receive an organ assessed with the full benefit of contemporary preservation technology. A patient listed at a smaller regional program may wait longer, receive an organ assessed under more limited conditions, or—in cases where organs are declined due to inadequate evaluation tools—not receive a suitable organ at all.

Toward Structural Reform

Addressing this problem requires engagement at multiple policy levels simultaneously. At the federal level, Congress and the Centers for Medicare and Medicaid Services could explore conditional reimbursement structures that incentivize technology adoption at under-resourced centers, analogous to existing mechanisms for other evidence-based interventions. The OPTN, in its ongoing restructuring, could incorporate technology access standards into transplant center certification requirements—not as punitive measures, but as triggers for federal support.

On the intellectual property side, compulsory licensing provisions—rarely invoked in the United States but available under existing law—could be examined as a mechanism for expanding access to preservation technology in contexts where the public health justification is demonstrably strong. Alternatively, federal procurement of perfusion systems for distribution to qualifying centers could reduce the market power currently exercised by dominant manufacturers.

None of these interventions is without complexity. Manufacturers have legitimate interests in recouping research and development investments. Regulatory standardization carries risks of rigidity. But the current arrangement—in which the survival prospects of a donated organ are partially determined by the patent portfolio of a device manufacturer—represents a policy failure that the transplant medicine community, health economists, and federal regulators have been too slow to name directly.

The organ shortage is real. But some portion of what appears to be scarcity is, in fact, the product of preventable technological inequity. Distinguishing between the two is not merely an academic exercise. For the patients waiting, it is the difference between a transplant and a statistic.